Tag: prostate cancer

SMALL SPEEDOS, BIG IMPACT! Thousands of Brave Daredevils Take to Mzansi’s Streets

Bloemfontein to Ballito, Paarl to Potchefstroom, Kimberley to Khayelitsha and Stellenbosch to Secunda, you name it, they did it! Thousands of men descended on the streets of Mzansi  for the 2026 Hollard Daredevil Run, freeing themselves from the confines of traditional running gear to wear only a purple speedo, all united by one important cause.

More than just a fun and memorable event, the Hollard Daredevil Run is an annual initiative that highlights the need for regular prostate and testicular cancers screening and encourages men to take proactive steps towards their health and wellbeing.

The main event took place at Zoo Lake in Johannesburg, with over 4 000 men causing quite a stir along Jan Smuts Avenue, Upper Park Drive, Oxford Road and surrounding suburbs.

“Every year, the support from Daredevils across South Africa has been truly remarkable. While the run is undoubtedly fun, it’s the meaningful cause, the sense of brotherhood and the shared purpose of creating awareness of male cancers that keeps Daredevils coming back year after year,” says Adél Kriel, Hollard South Africa’s Head of Experiential Marketing.

Across the country, hundreds of local runs brought communities together, spreading the message of men’s health and extending the impact of this nationwide movement.

This year, the event carried the bold tagline “Lekker Balls. Lekker Life”, reinforcing the potentially life-saving importance of early detection. Over the last seventeen years, the Hollard Daredevil Run has raised millions of Rands for the Cancer Association of South Africa (CANSA) and the Prostate Cancer Foundation (PCF), supporting education, screening programmes and life-saving services for men across the country.

“At Hollard, we want to help men and their families navigate uncertainty with greater confidence by challenging stereotypes and encouraging screening and early detection.

This year’s tagline, “Lekker Balls, Lekker Life” celebrates the idea that taking care of your health today means being more aware, prioritising regular screenings and getting checked early. Thank you to each and every participant and supporter for the difference they have made today,” she says.

Prostate and testicular cancers deserve attention, awareness and action. One in eight men is expected to be diagnosed with prostate cancer in their lifetime, with Black African men facing a 60% higher risk than other population groups. Prostate cancer is one of the leading causes of cancer-related deaths in South African men.

Testicular cancer, while less widespread, is most common in young men aged 15-49, affecting approximately 1 in every 250 males. When caught early, both cancers are highly treatable.

Last year’s Hollard Daredevil Run raised R1 200 000. This year, Hollard hopes to have an even greater impact.

While the 2026 event may be over, the opportunity to make a difference continues. South Africans are encouraged to support the cause by donating directly through the Hollard Daredevil Run BackaBuddy page.

How Have Diagnostic and Treatment Decisions for Prostate Cancer Changed in Recent Years?

Credit: Darryl Leja National Human Genome Research Institute National Institutes Of Health

An analysis of United States data reveals a broad shift away from overtreatment of low-risk prostate cancer. The analysis published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society, indicates a shift toward surveillance in response to concerns of overdiagnosis and overtreatment that have hindered screening in the recent past.

During the 2010s, recommendations supporting prostate-specific antigen–based screening for prostate cancer wavered due to growing concerns about the use of unnecessary treatment for slow-growing, localised cancers that posed no threat to patients’ lives. As a result, guidelines supported active surveillance for such low-risk prostate cancer.

To assess the extent to which this shift has translated into reduced treatment among patients, investigators analysed localised prostate cancer cases across the US. in the Surveillance, Epidemiology, and End Results Program (SEER; 2010–2023), the Veterans Affairs health system (VA; 2010–2024), and the Michigan Radiation Oncology Quality Consortium (MROQC; 2021-2025).

The researchers found that since 2010, low-risk prostate cancer has become less common at the time of diagnosis, while patients diagnosed with low-risk cancer increasingly avoid treatment. Specifically, low-risk prostate cancer at diagnosis declined from 28.8% to 24.0% in SEER and from 32.3% to 21.9% in the VA. Among patients diagnosed with low-risk cancer, receipt of neither radiation nor prostate removal increased from 33.6% to 83.4% in 2023 in SEER and from 51.6% to 96.3% in 2024 in the VA. Among 207 196 patients treated with radiation for localised prostate cancer, the proportion with low-risk disease declined from 33.7% to 6.5% in SEER and from 22.9% to 2.0% in the VA. In the more recent MROQC cohort, the proportion remained low, 2.8% to 4.2%, between 2021 and 2025.

“These data reflect broad changes in how prostate cancer is diagnosed and managed in the United States,” said lead author Steven M. Monda, MD, MSCI, of the University of Michigan. “We are seeing a moderate decline in the amount of low-risk prostate cancer being diagnosed, likely reflecting more magnetic resonance imaging use in screening. Moreso however, we are seeing that most of the low-risk prostate cancer is now being appropriately observed and not treated. This is a big win for patients because it means patients are avoiding the harms of unnecessary treatment for cancers that are unlikely to ever affect them.”

Source: Wiley

Why MRI is Changing Prostate Cancer Diagnoses

Preparing a patient for a prostate MRI

As we approach Movember with a focus on men’s health, we talk to Dr Hein Els, a radiologist specialising in abdominal imaging at SCP Radiology and Dr Louw-Waldi Vlok, a urologist at Mediclinic Panorama, about why MRI has become such an important tool in detecting prostate cancer and guiding diagnosis.

It’s often not the man who notices something first. His partner may mention noticing he has been up three or four times a night. He’ll put it down to getting older or having a cup of tea too late in the evening. What happens next is usually a visit to your GP…

How common is prostate cancer in the first place?

“Prostate cancer is the top invasive cancer reported in men in South Africa and also one of the most treatable, when it’s caught early,” says Dr Vlok. “Knowing what to look out for and understanding how far diagnosis and treatment have come, can reduce the fear and uncertainty around the disease. Today’s imaging technology means men get answers faster, treatment only when necessary and fewer invasive procedures than they would have a decade ago.”

What are the symptoms of prostate cancer?

“It is very important to realise that in the early stages of prostate cancer the patient will often have no symptoms at all”, says Dr Vlok. “Some men may have symptoms of an enlarging prostate which can include:  Needing to urinate more often, particularly at night, a weak or interrupted urine flow and even an inability to urinate and difficulty starting or stopping urination.

As the disease progress and grows beyond the prostate the symptoms will increase:

  • Blood in urine or semen
  • Pain in the pelvis or lower back

Are there any unusual or less obvious signs?

“Yes,” says Dr Vlok, “and these are the ones men are least likely to connect to the prostate.” In more advanced cases, prostate cancer can cause:

•           Unexplained pain in the lower back, hips or pelvis

•           New or worsening erectile difficulties

•           Unexplained weight loss or persistent fatigue

•           Swelling in the legs or feet

‘These signs can point to the cancer having spread beyond the prostate, most often to the bones. They can also have entirely unrelated causes, so the sensible response is to get checked rather than to worry. Catching a change early is exactly what makes modern diagnosis so effective.

These symptoms don’t automatically mean cancer. An enlarged prostate or inflammation of the prostate is common with age and usually benign, but any of these changes are worth mentioning to your doctor.

How was prostate cancer diagnosed before MRI?

For decades, the standard path was a physical examination and a PSA blood test. In many cases this is still the standard workup. The test measures the amount of prostate-specific antigen (PSA) in your blood. PSA is a protein produced by both cancerous and noncancerous tissue in the prostate, a small gland that sits below the bladder in males. If either raised concern, a biopsy followed.

This approach had/has a real drawback: Without imaging to guide it, a biopsy could miss cancer that was there or flag concern in men who didn’t actually need treatment. The biopsy itself was usually systematic. A urologist took a set number of tissue samples from across the prostate using ultrasound guidance, without being able to see whether any specific area actually looked suspicious. It worked but was something of a blind search. Some cancers were missed simply because the needle didn’t pass through them, while other men went through an invasive procedure and a period of anxious waiting, for a result that turned out to be low risk or clear. If the result was clear and symptoms carried on, only then would an MRI be ordered.

How does MRI fit into prostate cancer diagnosis now?

“This reactive approach was certainly not ideal,” says Dr Els. The international standard has fundamentally changed and the sequence is different. After a raised PSA result, the patient is usually sent to radiology for a multiparametric MRI of the prostate, before any biopsy is considered”, says Dr Els.

“This is a detailed scan that maps the prostate and identifies areas that look suspicious,’ Dr Els explains. ‘It’s non-invasive: No incisions, just a detailed set of images generated using magnetic fields rather than radiation. We review the scan and score any area of concern, so the urologist has a clear picture of where and how likely, anything significant might be. If there’s a concerning lesion, a targeted, MRI-US fusion guided biopsy is performed.”

The major advantage is that many men with a clear or low-risk MRI avoid a biopsy altogether. When an area does need sampling, the biopsy can be targeted precisely, which means fewer samples, a more accurate result and a much shorter path to an answer.

This shift is supported by the PRECISION and MRI-FIRST trials and endorsed by the European Association of Urology and the American Urological Association.

What does the MRI tell the specialist?

‘Once the prostate is imaged, we don’t just report whether something looks suspicious but we give it a score, says Dr Els. ‘This is called PI-RADS, short for Prostate Imaging Reporting and Data System and it runs from 1 to 5. The number tells your doctor how likely it is that what’s showing on the scan is aggressive cancer and whether a biopsy is worth doing at all.’

  • Scores 1 and 2: Usually mean no dangerous cancer is seen. Your doctor may simply monitor you over time
  • Score 3: The scan cannot give a clear answer either way. Doctors will look at other information, such as your PSA blood test, before deciding on a biopsy
  • Scores 4 and 5: Mean a high chance of cancer and a biopsy is usually recommended

This shift, from a blind search to a targeted, image-led approach, is one of the most significant improvements in prostate cancer care in the last 15 years and it’s an area in which SCP Radiology has invested heavily to get right.

Prostate cancer, when found early, has excellent outcomes. The combination of a simple blood test and non-invasive, expert-led imaging means most men now get a clear, accurate picture of their prostate health with far less uncertainty than in the past.

‘Our radiologists work closely with urologists across the circle of care, to make sure every scan is read with the depth of experience this diagnosis deserves,’ explains Dr Els.

And, if you’re reading this because you’ve noticed a change in someone else, not yourself: Raising it is worth the slightly awkward conversation. It’s often exactly what starts the process early.

FAQs

Is a prostate MRI painful or invasive?

No. It uses magnetic fields and involves no incisions.

If my PI-RADS score is low, do I still need a biopsy?

Usually not. A low score, 1 or 2, generally means your doctor will monitor you over time, rather than proceed to biopsy.

How long does the process take, from a raised PSA result to an answer?

This varies because the MRI is done before any biopsy. Many men reach a clear answer or avoid a biopsy altogether, in far fewer steps than under the older approach.

Is prostate cancer treatable if caught early?

Yes. It’s one of the most treatable cancers in men when detected early, which is why regular check-ups matter, even in the absence of symptoms.

Less than a Month to Go. ONE SMALL SPEEDO. ONE IMPORTANT CAUSE

Excitement builds ahead of the 2026 Hollard Daredevil Run

The countdown is officially on! There are only a few weeks to go until streets around Mzansi are awash with purple, and the excitement is mounting. Friday 23 October sees the 2026 Hollard Daredevil Run take place at Zoo Lake in Johannesburg and at various locations countrywide. 

This annual initiative, which this year carries the bold tagline “Lekker Balls. Lekker Life”, raises much-needed awareness about prostate and testicular cancers and reinforces the potentially life-saving importance of early detection. Over the last seventeen years, the support from Daredevils across South Africa, and beyond, has been nothing short of incredible. It is also the sense of brotherhood and shared purpose that keeps Daredevils coming back. 

The Hollard Daredevil Run is highly visible, with participants running 5km in a purple speedo, but its real purpose is getting South African men and their families talking about prostate and testicular cancers, understanding their risks and taking action through early detection.

“We know that thousands of men running in purple speedos gets people’s attention. What matters is what we do with that attention,” says Adél Kriel, Hollard South Africa’s Head of Experiential Marketing. “There is bravery in putting on a purple speedo in public, but behind this bold campaign is a very serious message: Know your risks, know your body and don’t put off getting checked. It could save your life.”

The more men who participate, the greater the funds raised for CANSA and the Prostate Cancer Foundation (PCF) to fund awareness campaigns, Prostate-Specific Antigen (PSA) screening and patient support. 

The 2026 Hollard Daredevil Run takes place at Zoo Lake in Johannesburg on Friday, 23 October at 15:00, with runs happening at various locations across the country on the same day. Details of run locations around the country will be shared on the Daredevil Run social media platforms.

Purple speedos are being snapped up fast, but there’s still time to secure your entry. Get your colleagues, friends, fellow students and family members to participate in the run as well as raising funds, and start a conversation about men’s health. After all, the Hollard Daredevil Run has always been about much more than the finish line.​

“This October, purple is more than a colour. It’s a conversation starter, but its real impact comes when that conversation extends beyond race day into families, workplaces and communities. The more people who take part, the further that message can reach,” says Kriel. “You don’t have to be a runner. You just have to be willing to show up for this important cause”.

Make a bold decision to make a difference by entering today at https://www.hollard.co.za/daredevilrun. Let’s make this year’s run the most impactful one yet.​

About Hollard  

The Hollard Insurance Group (“Hollard”) is South Africa’s largest privately owned insurance group. Hollard provides short-term, life insurance and investment products to a diverse customer base. Hollard through Hollard International has access to 10 markets across the continent namely South Africa, Botswana, Ghana, Lesotho, Mozambique, Namibia, Zambia, Kenya, Tanzania and Uganda.    

Study Finds the Optimal PSA Cutoff for Evaluating Prostate Cancer Treatment

Real-world study reveals the precise level associated with patient prognosis.

Credit: Darryl Leja National Human Genome Research Institute National Institutes Of Health

After treatment for metastatic prostate cancer, a drop in prostate-specific antigen (PSA) levels in the blood is an indicator that the treatment is working. A recent real-world study indicates that reaching a PSA level below 0.2 ng/mL is an indicator of improved patient survival. The study is published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society.

Multiple phase 3 clinical trials have shown that a PSA level below 0.2 ng/mL is the best cut-off for determining a patient’s prognosis. Real-world data are lacking, however, and physicians often use other metrics, such as percentage of PSA decline, to assess treatment response. To determine whether there is a PSA response target associated with the most favourable outcome in community-dwelling adults with metastatic prostate cancer, investigators analysed Veterans Health Administration data on 4890 patients who received testosterone deprivation therapy with or without other treatments in 2018–2023 for metastatic hormone-sensitive prostate cancer.

Over a median follow-up of approximately 2 years, 896 patients died. Patients whose PSA levels dropped below 0.2 ng/mL within 9 months of starting treatment were 54% less likely to die than patients whose levels did not drop this low, whether their PSA levels also decreased by at least 90% or not. Patients who had at least a 90% PSA decline but did not achieve a PSA of less than 0.2 ng/ml had no improvement in survival. The findings suggest that patients who do not experience a PSA drop below 0.2 ng/mL could be candidates for more aggressive treatments. Also, patients who received testosterone deprivation therapy plus another drug to further block testosterone were more likely to reach a PSA below 0.2 ng/mL.

“These data show that we need to target a PSA below 0.2 ng/ml as our metric of success to optimize outcomes for our patients with metastatic prostate cancer,” said corresponding author Stephen J. Freedland, MD, professor of Urology at Cedars-Sinai and Staff Physician at the Durham VA Medical Center.

Source: Wiley

Heroes in Purple Speedos Raise R1 200 000

Hollard Daredevil Run Hands over Funds Raised and Launches 2026 Campaign

Hollard has donated R1 200 000 to the Cancer Association of South Africa (CANSA) and the Prostate Cancer Foundation, with every rand raised by the purple speedo-clad heroes who took part in the 2025 Daredevil Run. At the same event, the 2026 campaign was officially launched and South African men will be called upon to lace up, strip down and do it all again!

Seventeen years in and the Hollard Daredevil Run shows no signs of putting its trousers back on. Under this year’s tagline “Lekker Balls; Lekker Life”, the 2026 cheque handover and campaign launch took place today at Hollard Campus in Parktown, Johannesburg.

The R1.2 million raised in the 2025 Hollard Daredevil Run was formally handed over to CANSA and the Prostate Cancer Foundation (PCF) to fund awareness campaigns, Prostate-Specific Antigen (PSA) screening and patient support. “The Hollard Daredevil Run is an unforgettable experience that raises awareness in a fun, engaging manner and sparks dialogue about men’s health in a non-threatening way,” saysHazel Chimhandamba, Group Chief Marketing Officer at Hollard.

“In 2024, we raised R1 million, 100% of which went directly to supporting prostate and testicular cancer awareness programmes. We are incredibly grateful to every Daredevil who dared to run in a purple speedo. It takes a special kind of bravery to turn heads for something that truly matters. Because behind all the laughs is a very serious mission: getting more men to check in on their health and each other,” adds Hazel.

The stakes are real. Prostate cancer remains one of the leading causes of cancer-related deaths in South African men. One in eight men is expected to be diagnosed with prostate cancer in their lifetime, with Black African men facing a 60% higher risk than other population groups. South Africa’s mortality rate due to prostate cancer is particularly high, largely due to underscreening, sociocultural stigmas and lack of health education.

Testicular cancer, while less widespread, is most common in young men aged 15-49, affecting approximately 1 in every 250 males. When caught early, it is highly treatable. A two-minute self-examination can detect lumps, swelling, or changes early, that’s considerably less time than it takes to run 5km in a purple speedo and the payoff is just as big.

A simple Prostate Specific Antigen (PSA) blood test for men over 40 can detect elevated protein levels before a single symptom appears. “The Hollard Daredevil donation is the largest single donation the PCF receives each year,” says Andrew Oberholzer, CEO of the Prostate Cancer Foundation of South Africa. “The funds help PCF distribute accurate, multilingual educational material and keep free PSA screening programmes running nationwide.”

He goes on to say that the run has also contributed to the development of South Africa’s first comprehensive prostate cancer registry, launching in 2026, which will track incidence, treatment and outcomes. The campaign further funds PCF’s helpline and support networks for men and families navigating a diagnosis.

Lorraine Govender, National Manager: Health Programmes of CANSA states, “The Hollard Daredevil Run has become far more than a fundraising event – it’s helped build a national movement that encourages men to speak openly about their health and seek help sooner. We are incredibly grateful to Hollard and every participant whose courage and commitment enable CANSA to continue providing awareness, early detection, screening and support services to men across South Africa.”

The event returns to Zoo Lake in Johannesburg on Friday, 23 October at 3pm with participants elsewhere able to register and run in their own neighbourhoods, workplaces, schools or universities anywhere in the country.

Registrations for the 2026 Hollard Daredevil Run open from 1 July and tickets will be available from Ticketpro at R200, which includes the courier of a registration pack and a complimentary purple speedo.

For more information, go to www.hollard.co.za/daredevilrun.

Do Prostate Cancer Drugs Interact with Certain Anticoagulants?

Study finds similar safety regardless of anticoagulant type

Photo by Kampus Production

In a study of adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and different types of anticoagulants, investigators found no evidence of an increase in patients’ bleeding or clotting risks, despite previous lab results that raised alarms. The findings are published by Wiley online in CANCER, a peer-reviewed journal of the American Cancer Society.

Thromboembolism, caused by a circulating blood clot that gets stuck and causes an obstruction, is the second leading cause of death in people with cancer, surpassed only by progression of the cancer itself. Anticoagulants (blood thinners) are standard therapy to treat or prevent thromboembolism. For individuals with advanced prostate cancer, thromboembolism can be especially worrisome because lab experiments have indicated that androgen-receptor pathway inhibitors, which are recommended for nearly all patients with advanced prostate cancer, can interact with certain anticoagulants – specifically, direct oral anticoagulants (DOACs).

To investigate whether these lab-based findings correlate to real concerns in patients, researchers evaluated outcomes in patients taking both anticoagulants and androgen-receptor pathway inhibitors, including enzalutamide, apalutamide, and abiraterone.

In the retrospective population-based analysis of 2997 Canadian adults with prostate cancer who were prescribed anticoagulants (DOACs or non-DOACs) and enzalutamide or apalutamide between 2012 and 2023, investigators found no increased risks of clotting in the DOAC versus non-DOAC groups. Similarly, investigators compared DOAC and non-DOAC groups combined with abiraterone and did not find an increased risk of bleeding.

“As clinicians, we are faced with the question of choosing the best anticoagulant option for patients on a daily basis, and the complexity further increases in patients with cancer taking many other medications including anticancer therapies that could cause concerning drug–drug interactions,” said lead author Tzu-Fei Wang, MD, of the University of Ottawa at The Ottawa Hospital and the Ottawa Hospital Research Institute. “Our findings suggest that pharmacokinetic drug–drug interaction concerns may not translate into adverse clinical outcomes in the real world. These results can help clinicians and patients feel more confident when managing anticoagulation alongside modern prostate cancer treatments.”  

Source: Wiley

Metformin May Echo the Benefits of Exercise in Prostate Cancer Care

Photo by Jonathan Borba on Unsplash

A new study has found that metformin may mimic one of exercise’s core biological effects in men with prostate cancer, raising levels of a molecule tied to energy balance and weight control even when patients are inactive. The findings suggest that metformin could help counter the metabolic strain of hormone therapy, when fatigue and other side effects often limit physical activity.

Led by physician-scientists at Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, the study appears in the journal EMBO Molecular Medicine.

Exercise is one of the most reliable ways to support health during cancer treatment. It helps regulate weight, blood sugar, and cardiovascular health – factors that shape how patients feel during therapy and how well they recover afterward.

For many people with cancer, however, regular exercise isn’t always feasible. Fatigue, hormone therapy, pain, or advanced disease can limit physical activity precisely when metabolic health becomes most important.

That reality has led researchers to ask a practical question: If exercise confers its benefits through specific biological signals, could some of those signals be activated in other ways?

According to the research, the answer may be yes. Sylvester investigators report that metformin raises levels of a naturally occurring molecule involved in how the body manages energy and weight in prostate cancer patients.

The finding does not suggest that a pill can replace physical activity. Instead, it offers insight into the internal pathways that underlie exercise’s metabolic benefits – and how those pathways might still be engaged when movement is limited.

“This study reflects what’s possible when laboratory science, metabolic biology, and clinical investigation are intentionally brought together for transdisciplinary studies,” said Sylvester researcher and first author, Marijo Bilusic, MD, PhD, genitourinary medical oncologist and professor of medicine and medical oncology at the Miller School. “The result isn’t a new cancer biomarker, but a clearer understanding of how a widely used drug may support metabolic health during prostate cancer treatment – an outcome that matters to patients and clinicians alike.”

The molecule at the heart of the study

At the center of the collaborative, team-science study is a molecule called N-lactoyl-phenylalanine (Lac-Phe). While its name is technical, its role is relatively simple.

Lac‑Phe is produced when the body is under metabolic demand. It forms when lactate, which accumulates during exertion, combines with phenylalanine, a basic building block of protein. Scientists first took notice of Lac‑Phe because its levels spike after intense exercise, coinciding with shifts in energy use and appetite regulation.

In preclinical and early human studies, higher Lac‑Phe levels have been associated with reduced appetite and improved weight control – two effects commonly linked to regular physical activity.

Lac-Phe does not rise only with exercise. Scientists observed elevated Lac-Phe levels in people taking metformin, even in the absence of physical activity. That overlap raised an important question for cancer care: Could a pathway typically associated with exercise be activated pharmacologically in patients whose treatments limit movement?

Why prostate cancer patients are a focus

To explore that question, the Sylvester team focused on prostate cancer, where hormone-based therapies are known to disrupt metabolism, contributing to weight gain, insulin resistance, and cardiovascular risk.

Notably, Lac-Phe levels in patients treated with metformin approximated those previously reported after strenuous exercise. This occurred even though patients were not exercising at the time of blood collection, and the effect persisted after hormone therapy began.

“From a clinical standpoint, seeing a metabolic signal that mirrors what we associate with intense exercise was striking,” said Bilusic. “For patients whose treatments or symptoms limit physical activity, that kind of effect could be especially meaningful.”

Higher Lac-Phe levels were not associated with anti-tumour response to metformin. The metabolite did not correlate with changes in prostate-specific antigen (PSA), a standard marker used to monitor prostate cancer.

What Lac-Phe might mean for patients

That distinction is central to the study’s interpretation. While more expanded studies are needed to determine the utility of Lac-Phe as a marker of anticancer efficacy, it appears to reflect how the body manages energy, weight and metabolic strain during treatment. These results were confirmed to ensure the findings were not limited to one clinical setting. In fact, increases were also observed in patients receiving other metabolic therapies, suggesting Lac-Phe may reflect a broader metabolic response rather than a drug‑specific effect.

“Cancer therapy often affects the body in ways that go beyond the tumour,” said Sylvester researcher Priyamvada Rai, PhD, co-leader, Tumor Biology Program and professor of radiation oncology at the Miller School. “Supporting metabolic health can influence how patients tolerate treatment and how they feel over time, even if it doesn’t directly change tumour growth. This study was an opportunity to investigate molecular pathways that can be therapeutically activated for better outcomes to treatments that induce metabolic stress.”

Metformin raises a stress hormone called GDF‑15, but this study found that Lac‑Phe was more closely tied to weight changes. Because the two didn’t rise together, metformin likely affects weight through multiple pathways, with Lac‑Phe playing a bigger role.

Taken together, the findings offer a clearer picture of how a widely used diabetes medication may influence metabolic health during prostate cancer care.

“What’s encouraging about this work is that it reminds us cancer care isn’t only about targeting tumours – it’s also about supporting the whole patient,” said Rai. “By better understanding how treatments affect metabolism, we can begin to identify ways to help patients maintain strength, resilience, and quality of life throughout their care.”

Source: University of Miami

New Trial Tests Lower Dose Treatments for Prostate Cancer

Credit: Darryl Leja National Human Genome Research Institute National Institutes Of Health

A major UK clinical trial co-led by researchers at UCL will test whether lower doses of common hormone therapies can treat advanced prostate cancer while reducing the severe side effects many patients experience.

The ENHANCE trial, jointly funded by Cancer Research UK and Prostate Cancer UK, will recruit 1,500 men with advanced prostate cancer from hospitals across the UK to compare standard and half-dose treatment using four commonly prescribed hormone drugs. UCL is sponsoring the trial and Professor Allan Hackshaw (Director of CRUK & UCL Cancer Trials Centre, UCL Cancer Institute) is joint-lead investigator, alongside Professors Ananya Choudhury and Peter Hoskin at the University of Manchester.

Men diagnosed with advanced prostate cancer, where the disease has spread beyond the prostate, are typically treated with powerful hormone therapies that slow tumour growth. While these drugs can extend life, they can also cause debilitating side effects such as extreme fatigue, hot flushes and high blood pressure, which can make it difficult for some patients to remain on treatment.

Researchers hope the £3.2 million ENHANCE trial will show that lower doses of these drugs can be just as effective while improving patients’ quality of life. The trial has not yet been launched and is awaiting the relevant regulatory and ethics approvals.

Professor Allan Hackshaw said: “Although focus is often on cancer trials to improve survival, we also need to find more tolerable ways of treating cancer without compromising survival. Side effects of cancer therapies matter a lot to patients, especially when they are frequent.

“We believe that several modern cancer drugs can be given at a much lower dose than what they were licensed for. Not only would this improve patient’s quality of life, but healthcare costs would be lower allowing more access especially in countries that cannot afford these drugs at their current high dose. The ENHANCE study can therefore influence clinical practice worldwide.

“Furthermore, Black men are more likely to get prostate cancer, and they too suffer from the same side effects of hormone treatment. They are often under-represented in clinical trials, so the ENHANCE study is a good opportunity to show that they get the same benefits from lowering the treatment dose as other ethnic groups.”

ENHANCE will compare full and half-dose treatment across four hormone therapies widely used for advanced prostate cancer: abiraterone, enzalutamide, darolutamide and apalutamide. If successful, the findings could influence prostate cancer treatment guidelines in the UK and internationally as early as 2030, improving care for thousands of men and reducing costs for the NHS.

Dr Ian Walker, Executive Director of Policy at Cancer Research UK, said: “Thanks to research, there’s been huge progress in prostate cancer treatments. Today, more than 8 in 10 men diagnosed with the disease in the UK will survive for 10 years or more. There’s more that can be done to save even more lives though, and in addition to finding more effective treatments, we need to find kinder ones too. The ENHANCE trial is looking to do just that and could mean that men affected by prostate cancer live not just longer lives but have a better quality of life.”

Dr Matthew Hobbs, Director of Research at Prostate Cancer UK, said: “No man should be forced to compromise between survival and their day-to-day wellbeing. This is a crucial issue for men with prostate cancer. That’s why Prostate Cancer UK is thrilled to be working alongside Cancer Research UK, pooling our resources and expertise to deliver the impact men need by funding this bold new trial that puts men’s wellbeing at its centre.”

Prostate cancer is now the most common cancer in UK men. Around 55 900* men are diagnosed each year. While survival rates have tripled since the 1970s, many men still face difficult side effects from treatment.

Retired solicitor Jonathan Edwards, 80, from Cheshire, experienced severe side effects after starting the hormone-blocking drug enzalutamide following his prostate cancer diagnosis in 2024, but when his nurse reduced the dose, his cancer remained under control and his quality of life improved dramatically.

Jonathan said: “It was such a shock when I was diagnosed. I had several health issues and after many tests was eventually told that I was suffering from prostate cancer and that it had spread beyond the prostate wall to my bones. I was referred to The Christie Hospital for treatment and was prescribed hormone blockers. The side effects made me extremely tired; I was sleeping through the day on and off and I had frequent hot flushes and generally felt weak.

“When the nurse suggested lowering the dose I was not sure what to expect. The difference soon became apparent and I felt normal again. I know that I will stay on the medication for as long as it is effective but, in the meantime, I am able to live a pretty normal life. I now exercise more and do not usually need an afternoon sleep. Happily, my PSA level started to go down until, after a few months, it was undetectable and has so far remained undetectable.

“My life has been transformed by the medication, my energy levels are higher, and I can socialise as normal. Traveling was a problem but now I can plan trips as long as I work around the 12-week cycle of injections and consultations. I am delighted that this trial has the potential to help other men going through the same thing in the future by enabling them to be treated for prostate cancer with their quality of life still largely intact.”

At least 10 per cent of trial participants will be Black men. Historically under-represented in clinical trials, Black men are often treated based on data that may be less applicable to them. Although data shows Black men are more likely to develop prostate cancer, more evidence is needed to understand their risk of aggressive disease and the role of overdiagnosis.

Alongside testing lower doses, the trial will collect tissue, blood and urine samples to identify biomarkers that could help determine which men are most suitable for reduced-dose treatment, shaping more personalised care in the future.

*Based on the average annual number of new cases of prostate cancer (ICD10 C61) diagnosed in the UK in the years 2018-2019, 2021.

Source: University College London

Prostate Cancer Screening on Par with Breast Cancer Screening

Credit: Darryl Leja National Human Genome Research Institute National Institutes Of Health

Prostate cancer screening compares favourably to screening for breast cancer in identifying significant cancers, reducing mortality and avoiding unnecessary harms, according to new research. The findings are presented on Sunday 15 March 2026 at the European Association of Urology Congress (EAU26) in London. The research is also accepted for publication in European Urology.

The researchers maintain that the similarities between the two forms of screening mean it is no longer rational to reject prostate cancer screening on one hand while endorsing screening for breast cancer on the other. Nevertheless, they recommend some caution given their research compares a trial with a population-based screening programme and across two different cancers. 

Although breast and prostate cancer are the most commonly diagnosed cancers in Europe amongst men and women respectively, screening for the diseases is vastly different. Organised breast cancer screening programmes have been established across Europe for more than three decades. Prostate cancer screening has lagged behind, primarily due to concerns around the effectiveness of the PSA blood test and the risks of overdiagnosis and overtreatment. Nevertheless, many men undergo variable, ‘opportunistic’ screening for the disease, mostly based on self-referral.

Several prostate cancer screening trials in Europe have now reported long-term outcomes, showing a reduced risk of death from prostate cancer [1]. This risk reduction is similar to that seen in breast screening programmes.

The new analysis compares the two types of cancer screening in terms of the effectiveness of the diagnostic tests and levels of overdiagnosis. The researchers, from the German Cancer Research Centre in Heidelberg, Germany, drew on data from the PROBASE prostate cancer screening trial in Germany and the country’s breast cancer screening programme.

They used data from 39,392 men who underwent an initial PSA blood test as part of the PROBASE trial at age 45 or 50. They compared this with data from just over 2.8 million women, aged 50–69, who had a mammography as part of Germany’s organised breast cancer screening programme. They found:

  • PSA blood testing followed by an MRI scan leads to a higher number of false positives than mammography (37-42% vs 10%).
  • A similar proportion of men and women were referred for biopsy (0.8-2.4% for men and 1.1% for women) as men in the PROBASE trial were triaged before referral using various factors to determine the likelihood of significant cancer (known as risk stratification)
  • Biopsies were far more likely to identify significant cancer in prostate screening than in breast screening (50-68% vs 10%), indicating that fewer men were referred for biopsy unnecessarily.
  • The percentages of invasive cancers identified were similar across both prostate and breast cancer screening (60-74% vs 73%).
  • Prostate cancer screening was more likely to identify non-aggressive cancers than breast cancer screening (26-31% vs. 22%). However, in prostate cancer the option of active surveillance is well-established, and the researchers maintain this would limit the risk of overtreatment. Active surveillance involves monitoring lower grade cancers and only starting treatment (radiotherapy or surgery) if they progress.

Dr Sigrid Carlsson, who leads Clinical Epidemiology of Early Cancer Detection at the German Cancer Research Centre (DKFZ) in Heidelberg, is lead author of the research. She said: “Until we have a population-based screening programme for prostate cancer, we can’t make an exact like-for-like comparison with breast cancer. But we can make some informed assumptions based on the data from our trial, which shows that if prostate cancer screening were extended to the wider population, then the outcomes are likely to be very similar to breast cancer. Although our study used German data, the findings are applicable to other countries. The final question we now need to answer is: what will this cost compared to what we are already paying for opportunistic screening? And that work is already underway.”

Tobias Nordström is a clinical urologist and Associate Professor at the Karolinska Institute, Sweden and a member of the EAU Scientific Congress Office. He said: “There is much that prostate cancer screening can learn from breast cancer screening and that is why this analysis is an important addition to our knowledge base. As these kinds of comparisons are very challenging, the results do need to be taken with a level of caution. That said, the clear overall similarities between the outcomes for breast and prostate cancer screening show that we are moving in the right direction, ensuring prostate cancer screening offers more benefits than harm.”

[1] See the 23-year follow-up from the European Randomised Study of Screening for Prostate Cancer (ERSPC) in the New England Journal of Medicine: European Study of Prostate Cancer Screening — 23-Year Follow-up | New England Journal of Medicine

Source: European Association of Urology